Ical trials. Further filesAdditional file 1: Table S1. Visual assessment (present/absent) of selected co-pathologies. (DOCX 16 kb) Extra file 2: Table S2. Biochemical measures of A1-40, A1-42, Ptau and T-tau (pg/mL) in MTG brain homogenate fractions (TBS [T], SDS [S] and Formic acid [F]) for both CTL and AD subjects. The total fraction would be the sum of all homogenate fractions. (DOCX 15 kb) Acknowledgments This study represents independent analysis partly funded by the National Institute for Well being Research (NIHR) Biomedical Investigation Centre at South London and Maudsley NHS Foundation Trust and King’s College London. Tissue samples have been supplied by The London Neurodegenerative Ailments Brain Bank, which receives funding from the UK Health-related Analysis Council and as a part of the Brains for Dementia Study programme, jointly funded by Alzheimer’s Investigation UK as well as the Alzheimer’s Society. The views expressed are these of your authors and not necessarily those of your NHS, the NIHR or the Department of Overall health. The datasets employed and/or analysed during the current study out there from the corresponding author on reasonable request. NJA is funded by the Wallenburg Centre for Molecular and Translational Medicine. TH is supported by a grant in the Hungarian Brain Research Plan. MS has received funding from the Knut och Alice Wallenberg Foundation (the Wallenberg Centre for Molecular and Translational Medicine), the Swedish Research Council plus the Swedish Alzheimer Foundation. KB holds the Torsten S erberg Professorship in Medicine and is supported by grants in the Swedish Research Council, the Swedish Alzheimer Foundation, as well as the Swedish Brain Foundation. HZ is often a Wallenberg Academy Fellow supported by grants from the Swedish Analysis Council, the European Investigation Council along with the UK Dementia Investigation Institute at UCL. AH is funded by Study Centre for Mental Health and Biomedical Research Unit for Dementia. Authors’ contributions NJA, AL and AH made the concept and design. All authors contributed to sample choice and/or interpretation of data. Information acquisition was performed by NJA, YML and AH. NJA and AL, carried out information evaluation and interpretation. NJA, AL, KB, HZ, AH drafted the manuscript and all authors revised. All authors study and authorized the final manuscript. Competing interests KB and HZ are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform firm in the University of Gothenburg. KB has served as a consultant or at advisory boards for Alzheon, Eli Lilly, Fujirebio Europe, IBL International, Novartis and Roche Diagnostics. HZ has served at advisory boards of Eli Lilly and Roche Diagnostics and has received travel help from TEVA. SL is definitely an employee of Johnson and Johnson.Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author facts 1 Department of Psychiatry and Neurochemistry, Institute of Neuroscience Physiology, the VSIR Protein HEK 293 Sahlgrenska Academy in the University of Gothenburg,Ashton et al. Acta Neuropathologica Communications(2019) 7:Page 10 ofM ndal, Sweden. 2Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. 3King’s College London, Institute of Psychiatry, Psychology Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK. 4NIHR Biomedical Investigation Centre for Mental Wellness Biomedical Analysis Unit for Dementia at South Lond.